ArticleJAMA oncology2017
Mitigating Financial Toxicity Among US Patients With Cancer.
Article in JAMA oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- First-line Nivolumab Plus Ipilimumab vs Sunitinib for Metastatic Renal Cell Carcinoma: A Cost-effectiveness Analysis.JAMA oncology · 2019Trial
- The Price of Care: Trends in Financial Transfers to Aging Parents.Journal of the American Medical Directors Association · 2026Article
- Article
- Adagrasib in the treatment of KRASTranslational cancer research · 2025Article
- Observational
- Cost-effectiveness of atezolizumab plus chemotherapy for advanced/recurrent endometrial cancer.Journal of gynecologic oncology · 2024Article
- Osimertinib in the treatment of resected EGFR-mutated non-small cell lung cancer: a cost-effectiveness analysis in the United States.Frontiers in pharmacology · 2024Article
- Factors Associated with Delaying and Forgoing Care Due to Cost among Long-term, Appalachian Cancer Survivors in Rural North Carolina.Cancer survivorship research & care · 2023Article
- First-line tremelimumab plus durvalumab and chemotherapyFrontiers in pharmacology · 2023Article
- Financial Toxicity of Cancer Care: An Analysis of Financial Burden in Three Distinct Health Care Systems.JCO oncology practice · 2021Article
- Health services utilization, out-of-pocket expenditure, and underinsurance among insured non-elderly cancer survivors in the United States, 2011-2015.Cancer medicine · 2021Article
- Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer.Frontiers in pharmacology · 2021Article
- Financial Toxicity in Head and Neck Cancer Patients Treated With Proton Therapy.International journal of particle therapy · 2021Article
- Understanding breast cancer survivors' financial burden and distress after financial assistance.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2020Article
- Article
- Global comparison of cancer outcomes: standardization and correlation with healthcare expenditures.BMC public health · 2019Article
- Cost-effectiveness of Maintenance Capecitabine and Bevacizumab for Metastatic Colorectal Cancer.JAMA oncology · 2019Article
- Assessing disparities in colorectal cancer mortality by socioeconomic status using new tools: health disparities calculator and socioeconomic quintiles.Cancer causes & control : CCC · 2017Article
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
27893021What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.